Literature DB >> 19443396

Genetic alterations in the PI3K pathway in prostate cancer.

Xiuju Sun1, Jian Huang, Taku Homma, Daisuke Kita, Helmut Klocker, Georg Schafer, Peter Boyle, Hiroko Ohgaki.   

Abstract

Alterations in the PIK3CA and PTEN genes were assessed in 40 prostate tumors (radical prostatectomy samples). Genetic analyses in glands of the highest Gleason pattern within each tumor revealed PIK3CA amplification in 13%, PIK3CA mutations in 3%, PTEN homozygous deletion in 13% and PTEN hemizygous deletion in 8% of the cases analyzed. Supporting the view that PTEN and PIK3CA act in the same PI3K signaling pathway, genetic alterations in the PIK3CA and PTEN genes were mutually exclusive, except in one tumor. Overall, 13 of the 40 (33%) prostate tumors had alterations in the PI3K pathway. For cases with genetic alterations, other tumor areas with lower Gleason patterns as well as non-tumorous prostate glands were also analyzed. Of nine tumors with Gleason score 7, five cases contained the same genetic alterations in tumor areas of Gleason patterns 3 and 4, whereas in another four cases, genetic alterations were detected only in tumor areas of Gleason 4 but not Gleason 3 patterns. There were no alterations in non-tumorous glands. These results suggest that genetic alterations in the PI3K pathway are common in prostate cancer, and occur mainly through PIK3CA amplification and PTEN hemizygous or homozygous deletion. Glands of Gleason pattern 3 are genetically heterogeneous, some containing the same genetic alterations observed in glands of Gleason pattern 4.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443396

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  29 in total

1.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

Review 2.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Martin C Abba; Fernando Benavides; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

Review 4.  The mutational landscape of prostate cancer.

Authors:  Christopher E Barbieri; Chris H Bangma; Anders Bjartell; James W F Catto; Zoran Culig; Henrik Grönberg; Jun Luo; Tapio Visakorpi; Mark A Rubin
Journal:  Eur Urol       Date:  2013-05-18       Impact factor: 20.096

Review 5.  Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik; Ayşe Özer
Journal:  Tumour Biol       Date:  2016-02-26

Review 6.  Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

7.  Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.

Authors:  Christine M Barnett; Michael C Heinrich; Jeong Lim; Dylan Nelson; Carol Beadling; Andrea Warrick; Tanaya Neff; Celestia S Higano; Mark Garzotto; David Qian; Christopher L Corless; George V Thomas; Tomasz M Beer
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 8.  Advancing precision medicine for prostate cancer through genomics.

Authors:  Sameek Roychowdhury; Arul M Chinnaiyan
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

Review 9.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

Review 10.  Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification.

Authors:  Jamie R Schoenborn; Pete Nelson; Min Fang
Journal:  Clin Cancer Res       Date:  2013-05-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.